REG - Trellus Health PLC - Launch of D2C IBS Offering

Trellus HealthAnnouncement

17/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230217:nRSQ2719Qa&default-theme=true

RNS Number : 2719Q  Trellus Health PLC  17 February 2023

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Launch of D2C IBS Offering, Expansion of Mount Sinai Agreement

and Related Party Transaction

 

Trellus now offering comprehensive Digestive Health solution

covering both IBD and IBS across both D2C and B2B2C channels

 

LONDON, U.K. AND NEW YORK, U.S. (17 February 2023): Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, personalized
resilience-driven self-management solution for chronic health conditions at
their intersection with mental health, announces the launch of its
Direct-to-Consumer ("D2C") offering for people living with Irritable Bowel
Syndrome ("IBS").

 

The Company also announces the expansion of one of its existing agreements
with the Mount Sinai Health System ("Mount Sinai"), under which the Trellus
Resilience Training and Self-Management Solution (the "Trellus Method") is
being made available as a wellness benefit to members of a large New York
State labour union which provides health services and benefits to its members
through Mount Sinai. This contract is now expanded to make the Trellus method
available to people living with IBS as well as to patients with inflammatory
bowel disease ("IBD"). The original contract with Mount Sinai was disclosed in
regulatory announcements made on 17 October and 20 December 2022.

 

Trellus Health has now launched its D2C offering for IBS, providing its
resilience-based methodology to support IBS patients' through coordinating and
delivering personalized behavioural, emotional and nutritional support
remotely via digital solutions, and provide access to an expert resilience
team via telehealth. The D2C offering will also help to drive awareness and
demand and further build an evidence base to support B2B2C engagement by
providing real-world evidence of the health and economic outcomes of the
Trellus Method and its application to chronic conditions.

 

The terms of the amended and restated Mount Sinai contract described above
(the "Contract") are not materially changed, save for the expanded
availability of the Trellus Method to members of the union with a diagnosis of
IBS in addition to those members diagnosed with IBD. As previously disclosed,
the Contract does not provide any guaranteed revenue but demonstrates further
execution of the Company's strategy to make the Trellus Method available to a
larger target patient population by addressing resilience in an IBS as well as
an IBD context.

 

IBS is a common condition affecting the digestive system, that has significant
similarities with IBD from a symptom burden and emotional perspective. IBS is
a chronic, lifelong problem which can have a big impact on an individual's
quality of life through both physical and mental psychological challenges. IBS
has a much higher population prevalence than IBD, impacting c. 30 million
patients in the United States (U.S.), compared to c. 3 million for IBD.

 

Whilst there is currently no cure for IBS, behavioural health approaches are
essential to managing and supporting the condition and its symptoms. Trellus
Health's personalized, resilience-driven self-management training programs are
designed specifically for people looking to overcome symptoms and emotional
burdens associated with IBS and IBD, and the Company believes its methods have
utility across a number of other chronic conditions.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "I am
delighted to be in a position to launch the Trellus Method for IBS program,
through both our D2C offering and by expanding one of our contracts with Mount
Sinai. Trellus now offers a comprehensive gastroenterology (GI) solution for
both IBS and IBD, and this represents the culmination of a lot of hard work by
the team.

 

"IBS affects around 30 million people in the U.S., and often has a significant
impact on a person's quality of life. We look forward to working with patients
and partners to further evaluate how the Trellus Method can empower those
suffering with IBD, and now also IBS, to achieve better health outcomes and
increased quality of life, with reduced healthcare costs."

 

Related Party Transaction Disclosures

The Trellus Method is based on technology developed by Mount Sinai faculty and
licensed to Trellus Health. Mount Sinai and Mount Sinai faculty, including Dr.
Marla Dubinsky, have a financial interest in Trellus Health. Mount Sinai has
representation on the Trellus Health Board of Directors.

Dr. Marla Dubinsky, CEO of Trellus Health, is a professor of pediatrics
(gastroenterology) and medicine (gastroenterology) at the Icahn School of
Medicine at Mount Sinai. As the Contract has the potential to generate revenue
which could exceed the relevant threshold for classification as a related
party transaction under the AIM Rules, the Contract is classified as a related
party transaction pursuant to the AIM Rules for Companies.

The independent directors of the Company (being Dr. Daniel Mahony, Mike
Salter, Christopher Mills and Traci Entel), having consulted with Singer
Capital Markets as the Company's Nominated Adviser, consider that the terms of
the Contract are fair and reasonable insofar as the Company's shareholders are
concerned.

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Dr. Marla Dubinsky, CEO and Co-Founder                   Via Walbrook PR

 Dr. Daniel Mahony, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage              Mob: 07980 541 893 / 07748 651 727 / 07867 984 082

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first resilience based digital health
company focused on the intersection of chronic illness and mental health.
Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden, building self-management
skills and promoting individual health behaviours that enable thriving in the
face of a chronic condition. Through its TrellusElevate™ connected health
platform and companion App, the company addresses both physical and
behavioural health together, in context, to improve outcomes and reduce
healthcare costs across the healthcare ecosystem.

 

The Company was initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common
struggles of self-management, Trellus Health considers its approach to have
potential utility and demand across many chronic conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. Patients with IBD treated using the methodology
also experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following starting the program(2).

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending GRITT™
resilience assessment and personalized resilience training methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

1) Source: https://www.cdc.gov/chronicdisease/about/costs/index.htm
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.cdc.gov_chronicdisease_about_costs_index.htm&d=DwMFaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=fSst1AtlXyuqcs3cHJXcCRilbI1Qm1WfjNYkVgQfiLE&m=IjQVBqsF0mJCc4cCch3kNewShI3X349VlYSUrh3C5-c&s=lilxcTv-hIGGEbeSix8wsDKl8TOyuP3Vw__GebvZFro&e=)
)

2) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) )

 

About the Trellus Health Digestive Health program

Trellus Health is pioneering a scientifically validated, personalized
resilience-driven self-management solution for chronic digestive health
conditions which addresses the intersection of chronic illness with mental
health, estimated to cost the US economy $3.7 trillion annually.(1) The
Trellus approach transforms chronic condition management and changes the lives
of patients living with debilitating, incurable conditions, initially focused
on IBD, including Crohn's Disease and ulcerative colitis, and IBS, but with
potential utility and demand across many chronic conditions.

 

The Digestive Health program is a self-management solution driven by
personalized resilience training. The program empowers and enables members to
manage their condition by teaching them to set goals, actively identify
challenges and solve problems associated with their condition, driving a
change of health behaviour to deliver improved outcomes and health status at
lower cost.

 

Patients with IBD and IBS face many challenges which are common across many
chronic conditions: the management of complex medication regimens, dealing
with symptoms and disability, monitoring physical indicators, maintaining
proper levels of nutrition, adjusting to the psychological and social demands
including difficult lifestyle adjustments, as well as engaging in effective
interactions with health providers.

 

Trellus Health'spersonalized resilience-driven self-management training
programs are designed specifically for people looking to overcome these
challenges. The aim is to enable patients and their physicians to achieve
better quality patient outcomes at a lower cost to health plans and employers,
and the proprietary resilience method has been proven to reduce unplanned
hospitalizations by 94% at the Mount Sinai IBD Center, New York, NY.(2)

( )

About Irritable bowel syndrome (IBS)

 

IBS is a common condition that affects the digestive system. It causes
symptoms like stomach pain, bloating, diarrhoea and constipation. These tend
to come and go over time, and can last for days, weeks or months at a time.
It's usually a chronic, lifelong problem which can be very frustrating to live
with and can have a big impact on an individual's everyday life. Whilst there
is currently no cure for the condition, behavioural health techniques, diet
changes and medicines can often help control the symptoms. The exact cause is
unknown - it's been linked to food passing through your gut too quickly or too
slowly, oversensitive nerves in a patient's gut, stress and a family history
of IBS.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFVRFIIDLIV